Composition comprising a combination of at least one proteolytic enzyme and at least one lipolytic enzyme, for use in preventing triglyceride synthesis

Abstract

The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The invention also has as an object such a composition for use as a drug, cosmetic agent, medical device, dietary composition, dietary supplement or nutraceutical, notably for use in preventing or treating obesity, atherosclerosis, type 2 diabetes or for use in preventing or reducing excess weight.

1 . A method for inhibiting or preventing synthesis or reformation of triglycerides in the enterocytes or cells of the intestine which comprises administering to a patient in need thereof a composition comprising a combination of at least one proteolytic enzyme and at least one lipolytic enzyme. 
     
     
         2 . The method of  claim 1 , wherein the proteolytic enzyme is selected from the group comprising subtilisin, nagarse, nattokinase, chymotrypsin, trypsin, elastase, thermolysin, serrapeptase, and mixtures thereof. 
     
     
         3 . The method of  claim 1  or  claim 2 , wherein the composition is in the form of a drug, cosmetic agent, medical device, dietary composition, nutraceutical or dietary supplement. 
     
     
         4 . The method of any  claim 1 , for prevention or reduction of excess weight, adipogenesis, excess cholesterol, or cellulite. 
     
     
         5 . The method of  claim 1 , for prevention or treatment of obesity, atherosclerosis or type 2 diabetes. 
     
     
         6 . The method of  claim 1 , wherein the composition is administered orally. 
     
     
         7 . The composition of  claim 1 , wherein the composition is in the form of a hard or soft capsule, tablet, granule, powder or oral solution. 
     
     
         8 . The method of  claim 7 , wherein the composition is in the form of a gelatin capsule or a gastro-resistant tablet. 
     
     
         9 . The method of  claim 1 , wherein the administration of the composition includes a daily dose of proteolytic enzyme of 50-100 mg. 
     
     
         10 . The method of  claim 1 , wherein the administration of the composition includes a daily dose of lipolytic enzyme of 200-300 mg. 
     
     
         11 . The method of  claim 1 , wherein the lipolytic enzyme is selected from the group comprising a lipase extracted from  Thermomyces lanuginosus, Rhizopus niveus, Penicillium roqueforti, Penicillium camemberti, Geotrichum candidum, Candida rugosa, Candida lipolytica, Candida parapsilosis, Aspergillus niger, Rhizopus oryzae, Mucor javanicus, Candida anthartica, Geotrichum candidum , oats, and mixtures thereof. 
     
     
         12 . The method of  claim 11 , wherein the lipase is a Cal A or Cal B lipase of  Candida anthartica, Geotrichum candidum, Candida rugosa , or a mixture of these lipases. 
     
     
         13 . A product for inhibiting or preventing synthesis or reformation of triglycerides in the enterocytes or cells of the intestine comprising:
 at least one proteolytic enzyme, and   at least one lipase, wherein said product is in the form of a hard or soft capsule, tablet, granule, powder or oral solution.   
     
     
         14 . The method of  claim 1 , wherein the proteolytic enzyme and the lipolytic enzyme are administered simultaneously, separately or sequentially. 
     
     
         15 . The method of  claim 2 , wherein the protelytic enzyme is subtilisin, nattokinase or a mixture thereof. 
     
     
         16 . The method of  claim 15 , wherein the lipase is a Cal A or Cal B lipase of  Candida anthartica, Geotrichum candidum, Candida rugosa , or a mixture of these lipases. 
     
     
         17 . The method of  claim 1 , wherein 2-monoacylglycerol is degraded in the intestine.